WuXi Biologics and Toregem BioPharma Sign MOU for Development of Anti-USAG-1 Antibody
SHANGHAI, Oct. 11, 2022 /PRNewswire/ -- WuXi Biologics and Toregem BioPharma Sign MOU for Development of Anti-USAG-1 Antibody
Source: prnasia.com
📰 Inflamm Regen News
Inflamm Regen News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Inflamm Regen. Real-time updates on events, politics, business and more.
WuXi Biologics and Toregem BioPharma Sign MOU for Development of Anti-USAG-1 Antibody
/PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), and Toregem...
Source: prnewswire.com
Aptorum Group Limited: Aptorum Group Enters Into Material Transfer and Exclusive Option-To-License Agreement with Yale University for Its Novel Immunomodulators Potentially Targeting Autoimmune and Oncology Diseases
(0) Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ("Aptorum Group" or "Aptorum"), a clinical-stage biopharmaceutical company, through its affiliate, has entered into a material transfer and option agreement ("Agreement") with Yale University ("Yale") to evaluate a group of preclinical stage novel immunomodulators. The novel immunomodulators may potentially target autoimmune and oncology diseases, including but not limited to, rheumatoid arthritis, lupus and sclerosis...
Source: finanznachrichten.de